Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Amgen CEO Says ‘I’m Leaving.’ Investors Say ‘Good Riddance’

After a decade as CEO, the oft-maligned Kevin Sharer will step down. That's giving shareholders holiday cheer as they bid the stock up on the news.

Researcher: J&J/Pharmacyclics Drug Could Be a Game-Changer

The experimental cancer drug Johnson & Johnson bought last week is receiving high praise, and could be "paradigm-shifting."

Covidien Follows Abbott With a Pharma Spin-Off

Could Sanofi, Novartis or GlaxoSmithKline be next to separate pharmaceutical development into a stand-alone company?

Pfizer Delivers Early Holiday Gifts to Shareholders

The company brings holiday cheer with its new stock repurchase program and dividend boost.

Abbott Labs Spinoff Looks Like the Right Move

Shareholders would likely be better served by the company's prescription drug business standing alone. Here's why.

Intuitive Surgical Shares Are In the Pink

Shares have surged as the company continues to be the dominant player in a fast-growing health care sector.

Why Eli Lilly Could Be a Lottery Stock Pick

If Eli Lilly is successful in delaying the progression of Alzheimer’s disease with its experimental drug, it could make Lipitor look like a mid-sized product. The odds?

Affymax Shares Hang on an FDA Decision

Affymax's stock price is swinging wildly as investors await a ruling on the company's promising kidney disease drug.

Investors Still Must Pick Generic Drug Companies By Hand

The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves.

Growing Medicare Patient Base Could Restore Luster to UnitedHealth Shares

UnitedHealth's latest deal is a deft move toward profiting off the growing number of retiring baby boomers.